

PATENT

Attorney Docket No. 015389-002600US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

9 1/2

In re application of:	)	
	)	
Thomas R. Cech et al.	)	Examiner: Toni Scheiner
	)	
Serial No.: 08/912,951	)	Art Unit: 1642
	)	
Filed: August 14, 1997	)	
	)	SUPPLEMENTAL INFORMATION
For: HUMAN TELOMERASE	)	DISCLOSURE STATEMENT UNDER
CATALYTIC SUBUNIT:	)	<u>37 C.F.R. § 1.97 and § 1.98</u>
DIAGNOSTIC AND THERAPEUTIC	)	
METHODS	)	

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached form PTO Form-1449 are being called to the attention of the Examiner. Some of these references were cited on a PCT Search Report for a corresponding application. For the Examiner's convenience, the references submitted are briefly summarized below.

Reference **GA** (U.S. Pat. 5,747,317) corresponds to previously submitted reference FE (a PCT publication).

Reference **GB** (U.S. Pat. 5,770,422) corresponds to previously submitted reference FD (a PCT publication).

Reference **GC** (WO 95/13382) corresponds to previously submitted reference AM (U.S. Pat. No. 5,489,508).

Reference **GD** (WO 96/01835) is a PCT publication, and corresponds to previously submitted reference AL (U.S. Pat. No. 5,583,016).

Reference **GE** (WO 98/08838) and Reference **GF** (WO 98/08938) do not appear to describe genes or proteins related to subject matter claimed in the present application.

RECEIVED  
TECH CENTER 1600/2960  
98 SEP 16 AM 11:15

Reference **GG** (WO 98/37181) is related to previously submitted references FN and FM.

Reference **GH** (WO 98/21343) is related to previously submitted reference FP.

Reference **GI** (Feng et al.) describes the RNA component (hTR) of human telomerase and is related to previously submitted reference AL (U.S. Pat. No. 5,583,016).

Pursuant to 37 C.F.R. § 1.98(d), copies of the references listed in the form PTO Form-1449 are not being provided. They were provided in U.S. Application Serial No. 08/854,050, filed May 9, 1997, a prior application to which the above-referenced application claims priority.

As provided for by 37 C.F.R. § 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits.

Respectfully submitted,



Randolph T. Apple  
Reg. No. 36,429

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111  
Phone: (650) 326-2400  
Fax: (650) 326-2422